CA3072735A1 - Processes for the preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate - Google Patents

Processes for the preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate Download PDF

Info

Publication number
CA3072735A1
CA3072735A1 CA3072735A CA3072735A CA3072735A1 CA 3072735 A1 CA3072735 A1 CA 3072735A1 CA 3072735 A CA3072735 A CA 3072735A CA 3072735 A CA3072735 A CA 3072735A CA 3072735 A1 CA3072735 A1 CA 3072735A1
Authority
CA
Canada
Prior art keywords
compound
formula
solvate
isotopologue
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3072735A
Other languages
English (en)
French (fr)
Inventor
John F. Traverse
Michael J. Zacuto
Weihong Zhang
Kirsten Faye Johnson
Maryll E. Geherty
Christopher Marton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CA3072735A1 publication Critical patent/CA3072735A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/313—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of doubly bound oxygen containing functional groups, e.g. carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/18—Preparation of optical isomers by stereospecific synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/70—Compounds containing any of the groups, e.g. isoureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA3072735A 2017-08-21 2018-08-20 Processes for the preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate Pending CA3072735A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548268P 2017-08-21 2017-08-21
US62/548,268 2017-08-21
PCT/US2018/000358 WO2019040109A1 (en) 2017-08-21 2018-08-20 PROCESSES FOR THE PREPARATION OF (S) -TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE

Publications (1)

Publication Number Publication Date
CA3072735A1 true CA3072735A1 (en) 2019-02-28

Family

ID=63794593

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3072735A Pending CA3072735A1 (en) 2017-08-21 2018-08-20 Processes for the preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate

Country Status (8)

Country Link
US (4) US10717703B2 (https=)
EP (1) EP3672939A1 (https=)
JP (2) JP7399846B2 (https=)
CN (2) CN111032628A (https=)
AU (1) AU2018321548B2 (https=)
CA (1) CA3072735A1 (https=)
MX (1) MX2020002010A (https=)
WO (1) WO2019040109A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
CN111606837A (zh) * 2020-06-15 2020-09-01 千辉药业（安徽）有限责任公司 一种维格列汀的合成方法
KR20240021198A (ko) * 2021-06-11 2024-02-16 오츠카 세이야쿠 가부시키가이샤 Erk 억제제의 제조 방법
CA3227425A1 (en) * 2021-07-26 2023-02-02 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound
CN114478324B (zh) * 2021-12-30 2023-07-07 上海嘉莱多生物技术有限责任公司 一种活性化合物及其在侧链羧基类化合物保护的应用
JP7808733B2 (ja) 2023-09-13 2026-01-29 ブリストル－マイヤーズ スクイブ カンパニー 置換オキソイソインドリニルピペリジン－２，６－ジオン化合物

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989812A (en) 1974-08-09 1976-11-02 Smithkline Instruments, Inc. Folic acid derivatives and use in radio-assay
CH613709A5 (en) 1975-12-10 1979-10-15 Ciba Geigy Ag Process for the preparation of glucosamine derivatives
JPS55111499A (en) 1979-02-21 1980-08-28 Takeda Chem Ind Ltd Glucosamine derivative and its preparation
US4406889A (en) 1980-02-15 1983-09-27 Ciba-Geigy Corporation Derivatives of aldohexoses, intermediates, processes for their manufacture, preparations containing such compounds, and their use
US4481190A (en) 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
JPS611651A (ja) 1984-06-12 1986-01-07 Toyama Chem Co Ltd Ｎ−アシル酸性アミノ酸ジアミド類およびその製造法並びにそれらを含有する抗潰瘍剤
US4690916A (en) 1984-11-13 1987-09-01 Syntex (U.S.A.) Inc. Nona and decapeptide analogs of LHRH useful as LHRH antagonists
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5556982A (en) 1985-01-14 1996-09-17 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5175343A (en) 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
HUT46044A (en) 1986-11-21 1988-09-28 Richter Gedeon Vegyeszet Process for producing immunstimulant peptides inhibiting multiplication of leukaemic cells and pharmaceutics comprising same
US4988496A (en) 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
IN173794B (https=) 1988-12-15 1994-07-16 Council Of Scient & Ind Res Ra
US5270302A (en) 1988-12-21 1993-12-14 Abbott Laboratories Derivatives of tetrapeptides as CCK agonists
HU205147B (en) 1989-06-29 1992-03-30 Sandoz Ag Process for producing muramyl dipeptide derivative and pharmaceutical compostions comprising same
IN177680B (https=) 1990-05-08 1997-02-15 Council Scient Ind Res
US5312831A (en) 1993-05-12 1994-05-17 American Cyanamid Company Urethanes and ureas that induce cytokine production
GB9326518D0 (en) 1993-12-29 1994-03-02 Sandoz Ltd Organic compounds
GB9408936D0 (en) 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
DE19505932B4 (de) * 1995-02-21 2005-06-23 Degussa Ag Verfahren zur Herstellung von Oxazolidinonen, neue Oxazolidinone sowie Verwendung von Oxazolidinonen
US5710129A (en) 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes
US5635504A (en) 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
IN184769B (https=) 1995-07-20 2000-09-30 Council Scient Ind Res
JPH09165370A (ja) 1995-10-13 1997-06-24 Fuji Yakuhin Kogyo Kk ラクタム誘導体およびその塩
GB9524267D0 (en) 1995-11-28 1996-01-31 Isis Innovation Enzyme inhibitor and method
WO1997031016A2 (en) 1996-02-23 1997-08-28 Ariad Pharmaceuticals, Inc. New inhibitors of sh2-mediated processes
US6117896A (en) 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
WO1998027209A1 (en) 1996-12-18 1998-06-25 Emory University Polycationic oligomers
EP1103560B1 (en) 1998-07-28 2006-12-27 Santen Pharmaceutical Co., Ltd. Novel thiazolidine derivatives
JP2000219663A (ja) 1998-11-24 2000-08-08 Taiho Yakuhin Kogyo Kk Ｎδ−置換アミノオルニチン誘導体及びその塩
KR20030011306A (ko) 2000-04-18 2003-02-07 일라이 릴리 앤드 캄파니 지질 ⅱ의 제조 방법
WO2001079268A2 (en) 2000-04-18 2001-10-25 Eli Lilly And Company A glycopeptide and preparation thereof
US7662960B2 (en) 2001-04-26 2010-02-16 Choongwae Pharma Corporation Beta-strand mimetics and method relating thereto
AU2002950136A0 (en) 2002-07-11 2002-09-12 La Trobe University N-methyl amino acids
US7314490B2 (en) 2002-08-22 2008-01-01 Victhom Human Bionics Inc. Actuated leg prosthesis for above-knee amputees
CN100522995C (zh) 2003-10-22 2009-08-05 中国医学科学院药物研究所 胞壁酰-丙氨酰-d-异谷氨酰胺衍生物、制法和其药物组合物与用途
US20050187138A1 (en) 2004-02-24 2005-08-25 The Regents Of The University Of California, A California Corporation Peptide beta-strand mimics based on pyridinones, pyrazinones, pyridazinones, and triazinones
WO2005100334A1 (en) 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
US7405237B2 (en) 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
DE102005014245A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen V
KR20080031379A (ko) 2005-07-11 2008-04-08 와이어쓰 글루타메이트 아그레카나제 저해제
CN1943341B (zh) 2006-08-04 2012-05-09 华南农业大学 氨基酸与农药的藕合物及其制备方法与作为农药的应用
ME02420B (me) 2006-09-26 2016-09-20 Celgene Corp 5-supstituirani derivati kinazolinona kao sredstva protiv raka
WO2008156701A2 (en) 2007-06-13 2008-12-24 The Brigham And Women's Hospital, Inc. Hydroxamate inhibitors of insulin-degrading enzyme and uses thereof
WO2009078040A2 (en) 2007-12-17 2009-06-25 Debatosh Datta Compounds inducing reperfusion in ischaemic tissues
CA2709553A1 (en) 2007-12-17 2009-06-25 Green Cross Therapeutics Private Ltd. Compound inducing angiogenesis response in ischaemic tissues
CZ305066B6 (cs) * 2008-02-25 2015-04-22 Zentiva, K.S. Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
US8344115B2 (en) 2008-04-21 2013-01-01 Chan-Sui Pang, legal representative Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples
AR072278A1 (es) * 2008-06-23 2010-08-18 Astrazeneca Ab Compuestos inhibidores de trombina
WO2010048423A1 (en) 2008-10-24 2010-04-29 Ark Diagnostics, Inc. Levetiracetam immunoassays
EP2373551B1 (en) 2008-12-09 2015-04-08 Sands Innovations Pty Ltd. A dispensing container
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
CN102219834A (zh) * 2011-04-14 2011-10-19 北京市丰硕维康技术开发有限责任公司 一种制备罗莫肽的方法
TWI547496B (zh) * 2011-10-04 2016-09-01 葛蘭素集團公司 抗菌化合物
CA3108974C (en) 2012-08-09 2023-04-04 Celgene Corporation Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US10189805B2 (en) 2014-09-09 2019-01-29 Vanderbilt University Metabolism probes for therapy and diagnosis
NZ731789A (en) * 2014-10-30 2019-04-26 Kangpu Biopharmaceuticals Ltd Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
CN104826544B (zh) 2015-04-02 2016-09-28 中国石油大学(华东) 含有偶氮苯光敏基团的脂肽分子表面活性剂及其合成方法

Also Published As

Publication number Publication date
AU2018321548A1 (en) 2020-03-05
CN118638025A (zh) 2024-09-13
CN111032628A (zh) 2020-04-17
US10717703B2 (en) 2020-07-21
US20190084924A1 (en) 2019-03-21
AU2018321548B2 (en) 2023-03-09
US11505522B2 (en) 2022-11-22
JP7665000B2 (ja) 2025-04-18
JP7399846B2 (ja) 2023-12-18
JP2024037802A (ja) 2024-03-19
EP3672939A1 (en) 2020-07-01
MX2020002010A (es) 2020-07-13
US20200299228A1 (en) 2020-09-24
US20230234914A1 (en) 2023-07-27
US11912644B2 (en) 2024-02-27
WO2019040109A1 (en) 2019-02-28
US12435028B2 (en) 2025-10-07
JP2020531500A (ja) 2020-11-05
US20240246899A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
CA3072735A1 (en) Processes for the preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate
JP7221861B2 (ja) オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物
CN105008325B (zh) 光学活性二胺化合物的制备方法
EA031470B1 (ru) Ингибиторы ido
CN1306425A (zh) 合成环加氧酶－2抑制剂的方法
CA3108974A1 (en) Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof
CN103265442A (zh) 一类新型截短侧耳素衍生物及其制备方法和抗肿瘤用途
ES2817909T3 (es) Procedimiento para la preparación de un intermedio de la sitagliptina mediante un método de reducción asimétrica
JP2025156455A (ja) チアゾロ［５，４－ｂ］ピリジンＭＡＬＴ－１阻害剤
RU2315044C2 (ru) Способ получения хиральных 1,4-дизамещенных пиперазинов
JP6848055B2 (ja) 薬学的使用のための鏡像異性的に純粋なシス‐イミダゾリン化合物を生成するための合成方法
US20240228475A1 (en) Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CA2912334C (en) New process to make non nucleosidal reverse transcriptase inhibitors (nnrti) for the treatment of hiv
WO2025262596A1 (en) Methods of making osivelotor
EA051931B1 (ru) Способы получения (s)-2-(2,6-диоксопиперидин-3-ил)-4-((2-фтор-4-((3-морфолиноазетидин-1-ил)метил)бензил)амино)изоиндолин-1,3-диона
WO2025211975A1 (en) Orexin receptor agonists
CN103209961A (zh) 用于制备2,3-二氨基丙酸衍生物的对映异构体形式的方法
NZ249022A (en) Preparation of (-)-(s)- and (+)-(r)- ethyl (5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido[3,4-b]pyrazin-7 -yl) carbamate; pyridyl amino hydroxamic acid precursors
WO2017098975A1 (ja) ビフェニル化合物の製造方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230816

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241118

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250318

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250326

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250715

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250715

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106